Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

PharmaZen doubles capacity to keep up with demand

PharmaZen doubles capacity to keep up with demand


Freeze dryer ­
PharmaZen chief executive Craig McIntosh inspects product
coming from the new freeze dryer.
Click to enlarge

Freeze dryer ­ PharmaZen chief executive Craig McIntosh inspects product coming from the new freeze dryer.

Freeze dryer ­
PharmaZen chief executive Craig McIntosh inspects product
coming from the new freeze dryer.
Click to enlarge

Freeze dryer ­ PharmaZen chief executive Craig McIntosh inspects product coming from the new freeze dryer.

For Immediate Release

Thursday, November 2

PharmaZen doubles capacity to keep up with demand


Biotechnology company PharmaZen has just invested $1m in plant and machinery which will double the company's potential turnover from $7 million to $14 million per year.

With demand outstripping supply for the company's animal and human health products, the cost of the new plant will be recovered very quickly.

Shares in PharmaZen are traded through the unregistered securities trading facility.

PharmaZen chief executive, Craig McIntosh, said the investment has predominantly been in milling and drying while other efficiencies had also been gained on the operational side with a significant investment in a heat recovery system.

The Company's most notable investment has been in a purpose designed vacuum drying system which can also be operated as a wet processing unit.

"We had looked around for an off the shelf solution which would enable us to wet process product and then continue through into a drying stage without the need to transfer product to another vessel (traditional technology). When we couldn't find a suitable solution we looked at the feasibility of having one designed and built, which is what we did."

The unit was finally commissioned in October and the company is extremely happy with the results, reporting not only the anticipated increase in throughput but an improvement in product yield due to reduced handling losses.

"There were a lot of teething problems which were always to be expected on such an innovative project and overall it took a lot longer than anticipated to have it up and running but in terms of performance it is better than we could have hoped for."

The plant upgrade is scheduled for completion early next month.

The new plant has been installed in PharmaZen's wholly-owned Waitaki Biosciences International unit in Christchurch where it manufactures a range of powder products extracted from a wide range of animal and marine sources. The range includes green-lipped mussel, shark cartilage, natural calcium and Chondroitin Sulphate. The products are used by other companies as a base for health products, mainly in the areas of bone health, joint health, immune and digestive support.


"We have always struggled to keep up with demand. Our level of efficiency was poor but that has increased markedly over the last 12 months and now we have the capacity to go to a new level," he said.

The company reported a loss of $183,000 on turnover of $5.58million for the 2005 year. It anticipates turnover of $6 million for 2006 with a significant lift in profit.


ENDS

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Media Mega Merger: StuffMe Hearing Argues Over Moveable Feast

New Zealand's two largest news publishers are appealing against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Elsewhere:


Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>

ALSO:


Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>

ALSO:

Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>